Current Report · Items 2.02, 9.01 · 8-K

Cellectar Biosciences, Inc.

CLRBNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On November 10, 2026, we issued a press release announcing our financial results for the quarter ended September 30, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

Filed Nov 10, 2026Accepted Nov 10, 2026, 7:25 AM ESTCIK 1279704Accession 0001104659-26-124790

View company →Permanent SEC source ↗

Press release in this filing

Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates →

Company context

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.

Current securities

CLRBNASDAQ · EQUITY · Current

Historical securities (2)

CLRBWNASDAQ · WARRANT · Historical · closed Aug 21, 2019 CLRBZNASDAQ · WARRANT · Historical · closed Apr 16, 2021

Recent company filings

Registered securities in this filing

Cellectar Biosciences, Inc. · 8-K · Filed 2026-11-10

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.00001 per share

Symbol: CLRB
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-11-10

Dimensions: Not supplied

Accession 000110465926124790 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Filed exhibits (1)

EX-99.1 (by filename) tm2629430d1_ex99-1.htm

Exhibit 99.1 Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström macroglobulinemia (WM) On track to dose first patients in the confirmatory Phase 3 trial of iopofosine I 131 in first quarter 2027 and to file for accelerated approval with the FDA in 1H 2027 Published case study of iopofosine I 131 highlighting a complete response lasting more than eight years in heavily pretreated diffuse large B-cell lymphoma patient Company to host webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., November 10, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a corporate update. “We remain focused on executing the clinical, regulatory and operational activities necessary to position iopofosine I 131 for potential registration and comm…

Open exhibit ↗

Get the free weekly BCS email.